Motley Fool: Amarin: Keep Your Dry Powder Ready

Even though I’m an unabashed bull for Amarin (NASDAQ:AMRN), I’ve never bought a single share of this promising biotech stock. The reason is that I’ve been waiting for a specific buying opportunity. Namely, the company’s upcoming advisory committee meeting for…

Advertisements

Motley Fool: 5 Top Pharmaceutical Stocks to Buy in 2019

More than $320 billion was spent on prescription drugs in the U.S. in 2016, a figure that’s expected to nearly double to $610 billion by 2021, according to IQVIA (formerly QuintilesIMS). With so much money being spent on necessary medicines,…

Motley Fool: 2 Healthcare Stocks Ripe for a Takeover

The healthcare sector has a well-earned reputation for ultra-pricey acquisitions. In 2017, for example, Gilead Sciences paid nearly $12 billion for Kite Pharma and its commercially unproven cell therapy platform. Kicking off this year, Bristol-Myers Squibb struck a $74 billion deal to…

Motley Fool: Stock Market Power Rankings: Apple Jacks

Each week, I’m ranking the biggest companies that trade on U.S. exchanges based on their size (market capitalization), momentum (total return over the past year), and recent news. Before we get to the rankings, a quick word on a major player.…

Motley Fool: Stock Market Power Rankings: Facebook Cashes In

Each week, I’m ranking the biggest companies that trade on U.S. exchanges based on their size (market capitalization), momentum (total return over the past year), and recent news. Before we get to the rankings, a quick word on a major player.…